Calliditas Therapeutics, Inc. (CALT) - סך הכנסות החברה

Calliditas Therapeutics (CALT) maintains a robust liquidity reserve, with marginal cash flow fully covering development costs. The business relies on an ecosystem of therapies for rare nephrological pathologies, retaining customers through the drug Tarpeyo. However, dependence on a single product and pressure from insurers create risks. The company's historical sales level on GURU.Markets shows that this metric equals 0.15.

For Calliditas Therapeutics (CALT), which is developing drugs against IgA nephropathy in the US, Europe, and China, this indicator serves as a measure of global expansion efficiency. It captures the actual cash flow from sales, neutralizing GAAP accounting delays, which allows for an assessment of the company's current commercial intensity based on annual sales volume and prevents overpaying for seasonal revenue spikes.